Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company focused on therapies for liver and viral diseases, and its news flow reflects progress across this pipeline. Company announcements frequently highlight developments in chronic hepatitis B virus (HBV) programs, obesity and metabolic dysfunction-associated steatohepatitis (MASH) research, and broader corporate activities.
News items include updates on pevifoscorvir sodium, an oral capsid assembly modulator (CAM-E) under investigation for chronic HBV infection. Aligos issues press releases on clinical trial milestones, such as the initiation and enrollment of the Phase 2 B-SUPREME study, as well as data presentations at major scientific meetings. These communications describe antiviral activity, biomarker changes, and study designs that are central to understanding the company’s HBV strategy.
Investors and observers can also find coverage of ALG-055009, a THR-β agonist being studied for obesity and MASH. News from Aligos has detailed nonclinical in vivo results in diet-induced obese mouse models, showing synergistic body weight and fat mass loss when ALG-055009 is combined with incretin receptor agonists such as semaglutide or tirzepatide. Such updates provide insight into how the company positions this candidate within emerging combination approaches in cardiometabolic disease.
Beyond pipeline data, the ALGS news stream includes corporate and financial disclosures such as quarterly business updates, financial results, inducement grants under Nasdaq Listing Rule 5635(c)(4), amendments to equity plans, and senior leadership appointments. The company also announces participation in healthcare and investor conferences, where members of management discuss strategy and development programs.
By following ALGS news, readers can track clinical progress, preclinical findings, capital and governance actions, and organizational developments that shape Aligos Therapeutics’ efforts in liver and viral disease therapeutics.
Aligos Therapeutics (Nasdaq: ALGS) announced the dosing of its first subject in the Phase 1a/b trial of ALG-000184, a novel treatment targeting hepatitis B virus (HBV). This trial aims to assess the safety, pharmacokinetics, and antiviral activity of ALG-000184 in patients with chronic hepatitis B. The company anticipates sharing initial topline results in the second half of 2021. The trial marks the second drug candidate from Aligos’s CHB portfolio to enter clinical studies this year, affirming their commitment to developing innovative therapies for unmet medical needs in liver diseases.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has priced its initial public offering of 10 million shares at $15.00 each, aiming for gross proceeds of approximately $150 million. The underwriters have a 30-day option for an additional 1.5 million shares. The common stock will commence trading on Nasdaq on October 16, 2020, with the offering expected to close on October 20, 2020, pending customary conditions. J.P. Morgan, Jefferies, and Piper Sandler are managing the offering.